Zhengye Biotechnology Holding, a Chinese provider of veterinary vaccines with a focus on livestock, raised $6 million by offering 1.5 million shares at $4, the low end of the range of $4 to $5.
Through its operating entity, the company focuses on the research, development, manufacturing, and sale of veterinary vaccines, with an emphasis on vaccines for livestock. Its product portfolio currently contains 44 veterinary vaccines, covering all major vaccines for livestock like swine and cattle, and it is also developing vaccines for household animals like dogs. Zhengye Biotechnology's products are available in 28 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt.
Zhengye Biotechnology Holding plans to list on the Nasdaq under the symbol ZYBT. Kingswood Capital Markets acted as sole bookrunner on the deal.
